« Back to Farmacia Journal 5/2013

EXENATIDE AND LIRAGLUTIDE – SIDE EFFECTS. COMPARATIVE CLINICAL STUDY

LUMINIŢA TIMOFTE^1,2, BERND STRATMANN¹, WULF QUESTER¹, MARIUS TRAIAN BOJIŢĂ², DIETHELM TSCHOEPE^1*

Download Full Article PDF

The objective of this study was to monitor the side effects of two agonists of GLP-1 (glucagon-like peptide 1), exenatide and liraglutide, in order to determine their safety, tolerability and therapeutic efficiency. The study took place in the Heart and Diabetes Center NRW, Germany and overweight patients with type 2 diabetes whose therapeutic regimen was switched to incretin mimetics were included. A validated questionnaire method was used to monitor the side effects during the hospitalization period, then again at 3, respectively 6 months after the beginning of the treatment. The therapy with liraglutide was associated with fewer side effects than the one with exenatide. In general, side effects were declining with time, thus, only few patients stopped the treatment. The incretin therapy turned out to be a safe and effective therapeutic option for patients with type 2 diabetes mellitus.